Marc-André Bédard

Marc-André Bédard

Professeur
Photo de Marc-André Bédard
Téléphone : (514) 987-3000 poste 0220
Local : SU-1205
Langues : Français, Anglais
Liens d'intérêt
Informations générales

Unités de recherche

Projets de recherche en cours

  • Imagerie cérébrale (PET scan) des systèmes cholinergiques dans les maladies neurodégénératives (Alzheimer, Parkinson ...)

Partenaires (organismes, entreprises)

  • Financement: Sociétés pharmaceutiques, IRSC et FRQS.

Affiliations externes principales

Enseignement
Distinctions

Directions de thèses et mémoires

Thèses de doctorat
Mémoires
Travaux dirigés
  • Semkovska, Maria. (2003). La neuropsychologie et la psychopharmacologie: exemples de fécondation réciproque. (Travail dirigé). Université du Québec à Montréal.
  • Lemay, Simon. (2002). Induction of a transient dysexecutive syndrome in Parkinson's disease using a subclinical dose of scopolamine. (Travail dirigé). Université du Québec à Montréal.
  • Duchesne, Nicole. (2000). ACUTE AND LONG-TERM ADMINISTRATION OF ANTICHOLINERGICS IN PARKINSON'S DISEASE: SPECIFIC EFFECTS ON THE SUBCORTICO-FRONTAL SYNDROME. (Travail dirigé). Université du Québec à Montréal.
Rapports d'activités et projets d'intervention
  • Scherer, Hélène. (1999). EFFETS DIFFERENTIELS DES NEUROLEPTIQUES A FORTE AFFINITE D2 ET D4 SUR L'APPRENTISSAGE PROCEDURAL DANS LA SCHIZOPHRENIE. (Rapport d'activités et projet d'intervention). Université du Québec à Montréal.

Publications

Articles scientifiques
  • Bédard, M.-A., Aghourian, M., Legault-Denis, C., Postuma, R.B., Soucy, J.-P., Gagnon, J.-F., Pelletier, A. et Montplaisir, J. (2019). Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: a PET imaging study with 18 F-FEOBV. Sleep Medicine, 58, 35–41. http://dx.doi.org/10.1016/j.sleep.2018.12.020.
  • Schmitz, T.W., Mur, M., Aghourian, M., Bédard, M.-A. et Spreng, R.N. (2018). Longitudinal Alzheimer’s degeneration reflects the spatial topography of cholinergic basal forebrain projections. Cell Reports, 24(1), 38–46. http://dx.doi.org/10.1016/j.celrep.2018.06.001.
  • Dulude, G., O'Connor, K., Audet, J.S. et Bédard, M.-A. (2017). Over facilitation of unadapted cognitive processes in obsessive compulsive disorder as assessed with the computerized mirror pointing task. Journal of Psychiatric Research, 89, 73–80. http://dx.doi.org/10.1016/j.jpsychires.2017.01.014.
  • Aghourian, M., Legault-Denis, C., Soucy, J.P., Rosa-Neto, P., Gauthier, S., Kostikov, A., Gravel, P. et Bédard, M.-A. (2017). Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18 F]-FEOBV. Molecular Psychiatry, 22, 1531–1538. http://dx.doi.org/10.1038/mp.2017.183.
  • Cyr, M., Parent, M.J., Mechawar, N., Rosa-Neto, P., Soucy, J.-P., Clark, S.D., Aghourian, M. et Bédard, M.-A. (2015). Deficit in sustained attention following selective cholinergic lesion of the pedunculopontine tegmental nucleus in rat, as measured with both post-mortem immunocytochemistry and in vivo PET imaging with [¹⁸F] fluoroethoxybenzovesamicol. Behavioural Brain Research, 278, 107–114. http://dx.doi.org/10.1016/j.bbr.2014.09.021.
  • Cyr, M., Parent, M.J., Mechawar, N., Rosa-Neto, P., Soucy, J.-P., Aliaga, A., Kostikov, A., Maclaren, D.A., Clark, S.D. et Bédard, M.-A. (2014). PET imaging with [¹⁸F]fluoroethoxybenzovesamicol ([¹⁸F]FEOBV) following selective lesion of cholinergic pedunculopontine tegmental neurons in rat. Nuclear Medicine and Biology, 41(1), 96–101. http://dx.doi.org/10.1016/j.nucmedbio.2013.10.004.
  • Parent, M.J., Bédard, M.-A., Aliaga, A., Minuzzi, L., Mechawar, N., Soucy, J.-P., Schirrmacher, E., Kostikov, A., Gauthier, S.G. et Rosa-Neto, P. (2013). Cholinergic Depletion in Alzheimer's Disease Shown by [18F]FEOBV Autoradiography. International Journal of Molecular Imaging, 2013, Article ID 205045. http://dx.doi.org/10.1155/2013/205045.
  • Parent, M.J., Cyr, M., Aliaga, A., Kostikov, A., Schirrmacher, E., Soucy, J.-P., Mechawar, N., Rosa-Neto, P. et Bédard, M.-A. (2013). Concordance between in vivo and postmortem measurements of cholinergic denervation in rats using PET with [18F]FEOBV and choline acetyltransferase immunochemistry. EJNMMI Research, 3, article 70. http://dx.doi.org/10.1186/2191-219X-3-70.
  • Parent, M., Bédard, M.-A., Aliaga, A., Soucy, J.-P., Landry St-Pierre, E., Cyr, M., Kostikov, A., Schirrmacher, E., Massarweh, G. et Rosa-Neto, P. (2012). PET imaging of cholinergic deficits in rats using [18F]fluoroethoxybenzovesamicol ([18F]FEOBV). NeuroImage, 62(1), 555–561. http://dx.doi.org/10.1016/j.neuroimage.2012.04.032.
  • Tremblay, P.L., Bédard, M.-A., Langlois, D., Blanchet, P.J., Lemay, M. et Parent, M. (2010). Movement chunking during sequence learning is a dopamine-dependant process: a study conducted in Parkinson’s disease. Experimental Brain Research, 205, 375–385. http://dx.doi.org/10.1007/s00221-010-2372-6.
  • Tremblay, P.-L., Bédard, M.-A., Levesque, M., Chebli, M., Parent, M., Courtemanche, R. et Blanchet, P.J. (2009). Motor sequence learning in primate: Role of the D2 receptor in movement chunking during consolidation. Behavioural Brain Research, 198(1), 231–239. http://dx.doi.org/10.1016/j.bbr.2008.11.002.
  • Paquet, F., Bédard, M.-A., Levesque, M., Tremblay, P.-L., Lemay, M., Blanchet, P.J., Scherzer, P., Chouinard, S. et Filion, J. (2008). Sensorimotor adaptation in Parkinson’s disease: evidence for a dopamine dependent remapping disturbance. Experimental Brain Research, 185, 227–236. http://dx.doi.org/10.1007/s00221-007-1147-1.
  • Levesque, M., Bédard, M.-A., Courtemanche, R., Tremblay, P.-L., Scherzer, P. et Blanchet, P.J. (2007). Raclopride-induced motor consolidation impairment in primates: role of the dopamine type-2 receptor in movement chunking into integrated sequences. Experimental Brain Research, 182, 499–508. http://dx.doi.org/10.1007/s00221-007-1010-4.
  • Rockwood, K., Black, S., Bédard, M.-A., Tran, T. et Lussier, I. (2007). Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study. International Journal of Geriatric Psychiatry, 22(4), 312–319. http://dx.doi.org/10.1002/gps.1675.
  • Boulet, C., Lemay, M., Bédard, M.-A., Chouinard, M.-J., Chouinard, S. et Richer, F. (2005). Early Huntington’s disease affects movements in transformed sensorimotor mappings. Brain and Cognition, 57(3), 236–243. http://dx.doi.org/10.1016/j.bandc.2004.09.001.
  • Semkovska, M., Bédard, M.-A, Godbout, L., Limoge, F. et Stip, E. (2004). Assessment of executive dysfunction during activities of daily living in schizophrenia. Schizophrenia Research, 69(2-3), 289–300. http://dx.doi.org/10.1016/j.schres.2003.07.005.
  • Gagnon, J.-F., Fantini, M.-L., Bédard, M.-A., Petit, D., Carrier, J., Rompré, S., Décary, A., Panisset, M. et Montplaisir, J. (2004). Association between waking EEG slowing and REM sleep behavior disorder in PD without dementia. Neurology, 62(3). http://dx.doi.org/10.1212/01.wnl.0000106460.34682.e9.
  • Paquet, F., Soucy, J.-P., Stip, E., Lévesque, M., Elie, A. et Bédard, M.-A. (2004). Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 16(1), 47–56. http://dx.doi.org/10.1176/jnp.16.1.47.
  • Lemay, S., Chouinard, S., Blanchet, P., Masson, H., Soland, V., Beuter, A. et Bédard, M.-A. (2004). Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28(1), 31–39. http://dx.doi.org/10.1016/S0278-5846(03)00172-6.
  • Lemay, S., Bédard, M.-A., Rouleau, I. et Tremblay, P.-L. (2004). Practice effect and test-retest reliability of attentional and executive tests in middle-aged to elderly subjects. The Clinical Neuropsychologist, 18(2), 284–302. http://dx.doi.org/10.1080/13854040490501718.
  • Scherer, H., Bédard, M.-A., Stip, E., Paquet, F., Richer, F., Bériault, M., Rodriguez, J.-P. et Motard, J.-P. (2004). Procedural learning in schizophrenia can reflect the pharmacologic properties of the antipsychotic treatments. Cognitive and Behavioral Neurology, 17(1), 32–40. http://dx.doi.org/10.1097/00146965-200403000-00004.
  • Quevillon, F. et Bédard, M.-A. (2003). Benzodiazépines : conséquences sur le fonctionnement mnésique des personnes âgées [Benzodiazepines: Consequences on memory in the elderly]. Santé mentale au Québec, 28(2), 23–41. http://dx.doi.org/10.7202/008615ar.
  • Schérer, H., Stip, E., Paquet, F. et Bédard, M.-A. (2003). Mild procedural learning disturbances in neuroleptic-naive patients with schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences, 15(1), 58–63. http://dx.doi.org/10.1176/jnp.15.1.58.
  • Lemay, S., Blanchet, P., Chouinard, S., Masson, H., Soland, V. et Bédard, M.-A. (2003). Poor tolerability of a transdermal nicotine treatment in Parkinson's disease. Clinical Neuropharmacology, 26(5), 227–229. http://dx.doi.org/10.1097/00002826-200309000-00004.
  • Semkovska, M., Stip, E., Godbout, L., Paquet, F. et Bédard, M.-A. (2002). Behavioral disorganization in schizophrenia during a daily activity: the kitchen behavioral scoring scale. Brain and Cognition, 48(2-3), 546–553. http://dx.doi.org/10.1006/brcg.2001.1415.
  • Duchesne, N., Soucy, J.-P., Masson, H., Chouinard, S. et Bédard, M.-A. (2002). Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: a single photon emission computed tomography study using 123iodine-β-CIT in patients on and off levodopa. Clinical Neuropharmacology, 25(4), 216–224. http://dx.doi.org/10.1097/00002826-200207000-00005.
  • Gagnon, J.-F., Montplaisir, J. et Bédard, M.-A. (2002). Les troubles du sommeil paradoxal dans la maladie de Parkinson [Rapid-eye-movement sleep disorders in Parkinson's disease]. Revue Neurologique, 158(2), 135–269.
  • Gagnon, J.-F., Bédard, M.-A., Fantini, M.-L., Petit, D., Panisset, M., Rompré, S., Carrier, J. et Montplaisir, J. (2002). REM sleep behavior disorder and REM sleep without atonia in Parkinson’s disease. Neurology, 59(4), 585–589. http://dx.doi.org/10.1212/wnl.59.4.585.
  • Semkovska, M., Bédard, M.-A. et Stip, E. (2001). Hypofrontalité et symptômes négatifs dans la schizophrénie : synthèse des acquis anatomiques et neuropsychologiques et perspectives écologiques [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives]. L'Encéphale, 27(5), 405–415.
    Obtenir ce livre à l'UQAMObtenir "Hypofrontalité et symptômes négatifs dans la schizophrénie : synthèse des acquis anatomiques et neuropsychologiques et perspectives écologiques [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives]" aux bibliothèques de l'UQAM
  • Rouleau, I., Imbault, H., Laframboise, M. et Bédard, M.-A. (2001). Pattern of intrusions in verbal recall: comparison of Alzheimer's disease, Parkinson's disease, and frontal lobe dementia. Brain and Cognition, 46(1-2), 244–249. http://dx.doi.org/10.1016/s0278-2626(01)80076-2.
  • Bédard, M.-A., Schérer, H., Stip, E., Cohen, H., Rodriguez, J.-P., et Richer, F. (2000). Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. Brain and Cognition, 43(1-3), 31–39. http://dx.doi.org/10.1006/brcg.1999.1133.
  • Bédard, M.-A., Pillon, B., Dubois, B., Duchesne, N., Masson, H. et Agid, Y. (1999). Acute and Long-Term Administration of Anticholinergics in Parkinson's Disease: Specific Effects on the Subcortico-Frontal Syndrome. Brain and Cognition, 40(2), 289–313. http://dx.doi.org/10.1006/brcg.1999.1083.
  • Bédard, M.-A., Lemay, S., Gagnon, J.-F., Masson, H. et Paquet, F. (1999). Induction of a transient dysexecutive syndrome in parkinson’s disease using a subclinical dose of scopolamine. Behavioural Neurology, 11, Article ID 316598. http://dx.doi.org/10.1155/1999/316598.
  • Bédard, M.-A., el Massioui, F., Malapani, C., Dubois, B., Pillon, B., Renault, B. et Agid, Y. (1998). Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. Clinical Neuropharmacology, 21(2), 108–117.
  • Montplaisir, J., Petit, D., Décary, A., Masson, H., Bédard, M.-A., Panisset, M., Rémillard, G. et Gauthier, S. (1997). Sleep and quantitative EEG in patients with progressive supranuclear palsy. Neurology, 49(4), 999–1003. http://dx.doi.org/10.1212/wnl.49.4.999.
  • Bédard, M.-A., Scherer, H., Delorimier, J., Stip, E. et Lalonde, P. (1996). Differential effects of D2- and D4-blocking neuroleptics on the procedural learning of schizophrenic patients. The Canadian Journal of Psychiatry, 41(7), S21–S24. http://dx.doi.org/10.1177/070674379604100704.
  • Bédard, M.-A., Montplaisir, J., Malo, J., Richer, F. et Rouleau, I. (1993). Persistent neuropsychological deficits and vigilance impairment in sleep apnea syndrome after treatment with continuous positive airways pressure (CPAP). Journal of Clinical and Experimental Neuropsychology, 15(2), 330–341. http://dx.doi.org/10.1080/01688639308402567.
  • Bédard, M.-A., el Massioui, F., Pillon, B. et Nandrino, J.L. (1993). Time for reorienting of attention: A premotor hypothesis of the underlying mechanism. Neuropsychologia, 31(3), 241–249. http://dx.doi.org/10.1016/0028-3932(93)90088-h.
  • Montplaisir, J., Bédard, M.-A., Richer, F. et Rouleau, I. (1992). Neurobehavioral manifestations in obstructive sleep apnea syndrome before and after treatment with continuous positive airway pressure. Sleep, 15(suppl. 6), S17–S19. http://dx.doi.org/10.1093/sleep/15.suppl_6.S17.
  • Pison, C., Bédard, M.-A., Malo, J. et Montplaisir, J. (1991). Effets d'une pression négative périthoracique continue sur les désaturations nocturnes des bronchopneumopathies chroniques obstructives [The effect of continuous peri-thoracic negative pressure on nocturnal desaturation of chronic obstructive bronchopneumopathies]. Revue des Maladies Respiratoires, 8(2), 219–224.
  • Bédard, M.-A., Montplaisir, J., Richer, F. et Malo, J. (1991). Nocturnal hypoxemia as a determinant of vigilance impairment in sleep apnea syndrome. CHEST, 100(2), 367–370. http://dx.doi.org/10.1378/chest.100.2.367.
  • Bédard, M.-A., Montplaisir, J., Richer, F., Rouleau, I. et Malo, J. (1991). Obstructive sleep apnea syndrome: pathogenesis of neuropsychological deficits. Journal of Clinical and Experimental Neuropsychology, 13(6), 950–964. http://dx.doi.org/10.1080/01688639108405110.
  • Lapierre, O., Montplaisir, J., Lamarre, M. et Bédard, M.-A. (1990). The effect of gamma-hydroxybutyrate on nocturnal and diurnal sleep of normal subjects: further considerations on REM sleep-triggering mechanisms. Sleep, 13(1), 24–30. http://dx.doi.org/10.1093/sleep/13.1.24.
  • Bédard, M.-A., Montplaisir, J., Godbout, R. et Lapierre, O. (1989). Nocturnal gamma-hydroxybutyrate. Effect on periodic leg movements and sleep organization of narcoleptic patients. Clinical Neuropharmacology, 12(1), 29–36. http://dx.doi.org/10.1097/00002826-198902000-00004.
  • Bédard, M.-A., Montplaisir, J. et Godbout, R. (1987). Effect of L-Dopa on periodic movements in sleep in narcolepsy. European Neurology, 27(1), 35–38. http://dx.doi.org/10.1159/000116126.
  • Montplaisir, J., Godbout, R., Poirier, G. et Bédard M.-A. (1986). Restless legs syndrome and periodic movements in sleep physiopathology and treatment with L-dopa. Clinical Neuropharmacology, 9(5), 456–463. http://dx.doi.org/10.1097/00002826-198610000-00006.